The near-elimination of cervical cancer mortality among young women in England marks a turning point in vaccine-preventable cancers. An analysis of national cancer and vaccination data, published in The Lancet, found that women offered the human papillomavirus (HPV) vaccine at age 12 or 13 now face an almost zero risk of dying from the disease before 30. Among those aged 20 to 24, no deaths were recorded during the study period. For vaccinated women aged 30 to 34, the risk of death was 63 per cent lower than for their unvaccinated peers. The vaccine prevents roughly 90 per cent of cervical cancers, which are caused by high-risk HPV strains.

A separate observational study, drawing on medical records of 509,926 individuals who entered US nursing homes between 2017 and 2022, points to an unexpected protective association. Researchers at Brown University found that residents who received the recombinant shingles vaccine Shingrix within a year of admission had a 24 per cent lower incidence of dementia over a four-year follow-up compared with the unvaccinated. The study cannot establish causation, and the authors caution that vaccinated individuals may have been healthier overall. Proposed mechanisms include the prevention of shingles-related neuroinflammation and stroke, or a broader immune-stimulating effect that benefits brain health.

The findings arrive as health authorities worldwide intensify efforts to expand vaccine coverage. The UAE’s Ministry of Health and Prevention convened a dialogue session to shape a national roadmap for eliminating HPV-related diseases, drawing on Sweden’s experience and international best practices in vaccination, screening and public awareness. In India, where 1.5 million new cancer cases are reported each year, the Union health minister stressed that prevention and early diagnosis remain the most effective weapons against the growing cancer burden. Telangana state has made cancer a notifiable disease and established registries and district-level care centres.

The World Health Organization’s cervical cancer elimination strategy calls for 90 per cent of girls to be fully vaccinated against HPV by age 15 by 2030. Yet health officials in England warn that declining vaccine uptake could reverse hard-won gains. For the shingles-dementia link, confirmatory studies are needed to move from association to evidence of a causal protective effect. The next milestone for HPV vaccination programmes will be monitoring whether the zero-mortality pattern holds as vaccinated cohorts age, while researchers await results from controlled trials that could clarify whether Shingrix offers a modifiable pathway to reduce dementia risk.